Salicylates When Used As Fragrance Ingredients Q

Total Page:16

File Type:pdf, Size:1020Kb

Salicylates When Used As Fragrance Ingredients Q Available online at www.sciencedirect.com Food and Chemical Toxicology 45 (2007) S318–S361 www.elsevier.com/locate/foodchemtox Review A toxicologic and dermatologic assessment of salicylates when used as fragrance ingredients q The RIFM Expert Panel D. Belsito a, D. Bickers b, M. Bruze c, P. Calow d, H. Greim e, J.M. Hanifin f, A.E. Rogers g, J.H. Saurat h, I.G. Sipes i, H. Tagami j a University of Missouri (Kansas City), c/o American Dermatology Associates, LLC, 6333 Long Avenue, Third Floor, Shawnee, KS 66216, USA b Columbia University Medical Center, Department of Dermatology, 161 Fort Washington Avenue, New York, NY 10032, USA c Malmo University Hospital, Department of Occupational & Environmental Dermatology, Sodra Forstadsgatan 101, Entrance 47, Malmo SE-20502, Sweden d Institut for Miliovurdering, Environmental Assessment Institute, Linne´sgade 18, 1st floor, Copenhagen 1361 K, Denmark e Technical University of Munich, Institute for Toxicology & Environmental Hygiene, Hohenbachernstrasse 15-17, Freising-Weihenstephan D-85354, Germany f Oregon Health Sciences University, Department of Dermatology L468, 3181 SW Sam Jackson Park Road, Portland, OR 97201-3098, USA g Boston University School of Medicine, Department of Pathology and Laboratory Medicine, 715 Albany Street, L-804, Boston, MA 02118-2526, USA h Hospital Cantonal Universitaire, Clinique et Policlinique de Dermatologie, 24, Rue Micheli-du-Crest, Geneve 14 1211, Switzerland i Department of Pharmacology, University of Arizona, College of Medicine, 1501 North Campbell Avenue, P.O. Box 245050, Tucson, AZ 85724-5050, USA j 3-27-1 Kaigamori, Aoba-ku, Sendai 981-0942, Japan Abstract An evaluation and review of a structurally related group of fragrance materials. Ó 2007 Published by Elsevier Ltd. Keywords: Safety; Review; Salicylates; Fragrance Contents 1. Chemical identity and exposure (Table 1). S319 1.1. Estimated consumer exposure. .............................................................. S323 2. Absorption, distribution and metabolism, and potential for enzyme induction. S323 2.1. Absorption . ........................................................................... S323 2.1.1. Percutaneous absorption (Tables 2–5)................................................ S323 2.1.2. Oral absorption. S325 2.1.3. Inhalation absorption . S326 2.2. Distribution and pharmacokinetics ........................................................... S326 2.3. Metabolism (Fig. 1)...................................................................... S327 3. Toxicological studies . S329 3.1. Acute toxicity (Tables 6a–6c)............................................................... S329 3.2. Subchronic toxicity (Table 7)............................................................... S330 3.2.1. Dermal studies . S330 q All correspondence should be addressed to: A.M. Api, 50 Tice Boulevard, Woodcliff Lake, NJ 07677, USA. Tel.: +1 201 689 8089; fax: +1 201 689 8090. E-mail address: [email protected] 0278-6915/$ - see front matter Ó 2007 Published by Elsevier Ltd. doi:10.1016/j.fct.2007.09.066 D. Belsito et al. / Food and Chemical Toxicology 45 (2007) S318–S361 S319 3.2.2. Oral studies . S333 3.2.3. Summary of subchronic toxicity studies. S333 3.3. Chronic toxicity (Table 8) ................................................................. S334 3.3.1. Repeated-dose toxicity of salicylate metabolites . S335 3.4. Mutagenicity and genotoxicity . ............................................................. S335 3.4.1. Bacterial studies (Table 9)........................................................ S335 3.4.2. Mammalian studies (Table 10)..................................................... S336 3.4.3. Summary of the genotoxicity data . S336 3.5. Carcinogenicity ......................................................................... S337 3.5.1. Non-standard carcinogenicity studies . S337 3.5.2. Anti-carcinogenic effects . S337 3.5.3. Summary of the carcinogenicity data . S337 3.6. Reproductive and developmental toxicity (Table 11).............................................. S337 3.6.1. Summary of the reproductive and developmental toxicity . S339 3.7. Skin irritation .......................................................................... S341 3.7.1. Human studies (Table 12)........................................................ S341 3.7.2. Animal studies (Table 13) ........................................................ S341 3.7.3. Summary of the skin irritation data . S341 3.8. Mucous membrane (eye) irritation (Table 14)................................................... S345 3.9. Skin sensitization ........................................................................ S345 3.9.1. Human studies (Table 15)........................................................ S345 3.9.2. Cross sensitization. S345 3.9.3. Animal studies (Table 16) ........................................................ S345 3.9.4. Summary of the skin sensitization data . S346 3.10. Phototoxicity and photoallergenicity (Tables 17–19) .............................................. S351 3.10.1. Human studies . S351 3.10.2. Animal studies . S351 3.11. Environmental toxicity .................................................................... S352 4. Summary . S353 5. Conclusion . S354 Conflict of interest statement . S355 References . S355 1. Chemical identity and exposure (Table 1) individual chemicals. The group summary is an evaluation of relevant data selected from the large bibliography of This report summarizes scientific data relevant to the studies and reports on the individual chemicals. The risk assessment of the use of salicylates as fragrance ingre- selected data were deemed to be relevant based on the dients (Table 1). The 17 salicylates considered here nature of the protocols, quality of the data, statistical sig- include alkyl (i.e., methyl-, ethyl-, butyl-, isobutyl-, pen- nificance, and appropriate exposure. These data are pre- tyl-, isoamyl-, hexyl-, and ethyl hexylsalicylate), alkenyl sented in tabular form in the group summary. The (i.e., cis-3-hexenyl-, trans-2-hexenyl-, 1,3-dimethyl-3-bute- Fragrance Material Reviews on each individual salicylate nyl, and 3-methyl-2-butenyl salicylate), aromatic ring contain a comprehensive summary of published and (i.e., benzyl-, phenyl-, p-cresyl- and phenethyl salicylate) unpublished reports and comprehensive bibliographies. and other (i.e., 4-methylsalicylate) derivatives of salicylic Salicylates are ingredients of many fragrances. They may acid. Most of these substances are used as fragrance be found in decorative cosmetics, fine fragrances, sham- and flavor ingredients. This report presents and synthe- poos, toilet soaps and other toiletries as well as in non-cos- sizes animal and human data, including studies by various metic products such as household cleaners and detergents. routes of exposure, and emphasizes the risk assessment Many of the salicylates assessed in this report have been for use of salicylates as fragrance ingredients. The scien- evaluated and approved for use as flavor ingredients in tific evaluation focuses on dermal exposure, which is con- foodstuffs. In the United States, 5 of the 17 salicylates sidered to be the primary exposure route for fragrance (ethyl salicylate, isobutyl salicylate, isoamyl salicylate, ben- materials. Where relevant, toxicity, metabolism and bio- zyl salicylate, and phenethyl salicylate) have been approved logical fate data from other routes of exposure have also for use as flavors by the Food and Drug Administration been considered. (FDA) in accordance with (21 CFR 172.515). In addition, The current format for these RIFM publications methyl (2475), ethyl (2458), butyl (3650), isobutyl (2213), includes a summary evaluation paper of the chemical isoamyl (2084), benzyl (2151), phenyl (3960), phenethyl group and individual Fragrance Material Reviews on the (2868) salicylate have been granted Generally Recognized S320 D. Belsito et al. / Food and Chemical Toxicology 45 (2007) S318–S361 Table 1 Material identification, summary of volume of use, and dermal exposure Material Synonyms Structure Worldwide Dermal systemic exposure in Maximum metric tons cosmetic products (mg/kg/day) skin level (%) Benzyl salicylate Benzoic acid, 2-hydroxy-, >1000 0.4023 6.71 phenylmethyl ester; CAS# 118-58-1 Benzyl 2-hydroxybenzoate; Molecular weight: Benzyl o-hydroxybenzoate; 228.25 Log Kow 2-Hydroxybenozic acid; (calculated): 4.31 Phenylmethyl 2- hydroxybenozate; Salicylic acid, benzyl ester Butyl salicylate Benzoic acid, 2-hydroxy-, butyl <0.01 0.0005a 0.02 ester; CAS# 2052-14-4 n-Butyl o-hydroxybenzoate; Molecular weight: 194.23 LogKow n-Butyl salicylate (calculated): 4.08 p-Cresyl salicylate Benzoic acid, 2-hydroxy-, < 0.01 0.0003 0.001 4-methylphenyl ester; CAS# 607-88-5 p-Tolyl salicylate Molecular weight: 228.25 LogKow (calculated): 4.37 1,3-Dimethyl-3- Benzoic acid, 2-hydroxy-, 1,3- 0.1–1.0 0.0005a 0.02 butenyl salicylate dimethyl-3-butenyl ester CAS # 80118-10-1 Molecular weight: 220.26 LogKow (calculated): 4.91 Ethyl hexyl Benzoic acid, 2-hydroxy-, 2- 0.1–1.0 0.0005a 0.02 salicylate ethylhexyl ester; Dermoblock OS; Escalol 587; 2-Ethylhexyl 2- hydroxybenzoate; CAS# 118-60-5 2-Ethylhexyl salicylate; Molecular weight: Eusolex OS; 250.34 LogKow Heliosol 2; (calculated): 5.97 Neo Heliopan; Type OS; Neotan L; Salicylic acid 2-ethylhexyl ester; Trivent OS Ethyl salicylate Benzoic acid, 2-hydroxy-, ethyl 1–10 0.0002 0.14 ester; CAS# 118-61-6 Ethyl 2-hydroxybenzoate; Molecular weight: Ethyl o-hydroxybenzoate: 166.18 LogKow Ethyl salicylate;
Recommended publications
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Lyme Disease (Chronic)
    Dr.
    [Show full text]
  • Dimethyl Sulfoxide MSDS
    He a lt h 1 2 Fire 2 2 0 Re a c t iv it y 0 Pe rs o n a l Pro t e c t io n F Material Safety Data Sheet Dimethyl sulfoxide MSDS Section 1: Chemical Product and Company Identification Product Name: Dimethyl sulfoxide Contact Information: Catalog Codes: SLD3139, SLD1015 Sciencelab.com, Inc. 14025 Smith Rd. CAS#: 67-68-5 Houston, Texas 77396 RTECS: PV6210000 US Sales: 1-800-901-7247 International Sales: 1-281-441-4400 TSCA: TSCA 8(b) inventory: Dimethyl sulfoxide Order Online: ScienceLab.com CI#: Not applicable. CHEMTREC (24HR Emergency Telephone), call: Synonym: Methyl Sulfoxide; DMSO 1-800-424-9300 Chemical Name: Dimethyl Sulfoxide International CHEMTREC, call: 1-703-527-3887 Chemical Formula: (CH3)2SO For non-emergency assistance, call: 1-281-441-4400 Section 2: Composition and Information on Ingredients Composition: Name CAS # % by Weight Dimethyl sulfoxide 67-68-5 100 Toxicological Data on Ingredients: Dimethyl sulfoxide: ORAL (LD50): Acute: 14500 mg/kg [Rat]. 7920 mg/kg [Mouse]. DERMAL (LD50): Acute: 40000 mg/kg [Rat]. Section 3: Hazards Identification Potential Acute Health Effects: Slightly hazardous in case of inhalation (lung irritant). Slightly hazardous in case of skin contact (irritant, permeator), of eye contact (irritant), of ingestion, . Potential Chronic Health Effects: Slightly hazardous in case of skin contact (irritant, sensitizer, permeator), of ingestion. CARCINOGENIC EFFECTS: Not available. MUTAGENIC EFFECTS: Mutagenic for mammalian somatic cells. Mutagenic for bacteria and/or yeast. TERATOGENIC EFFECTS: Not available. DEVELOPMENTAL TOXICITY: Not available. The substance may be toxic to blood, kidneys, liver, mucous membranes, skin, eyes.
    [Show full text]
  • Safety Assessment of Benzyl Salicylate As Used in Cosmetics
    Safety Assessment of Benzyl Salicylate As Used in Cosmetics Status: Draft Report for Panel Review Release Date: November 9, 2018 Panel Meeting Date: December 3-4, 2018 The 2018 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Alice Akinsulie, Scientific Writer/Analyst. © Cosmetic Ingredient Review 1620 L Street, NW, Suite 1200 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢ [email protected] Commitment & Credibility since 1976 Memorandum To: CIR Expert Panel Members and Liaisons From: Alice Akinsulie, Scientific Analyst/Writer Date: November 9, 2018 Subject: Draft Safety Assessment of Benzyl Salicylate as Used in Cosmetics Enclosed is the Draft Report of the Safety Assessment of Benzyl Salicylate as Used in Cosmetics. (It is identified as bensal122018rep in the pdf document.) On October 9, 2018, CIR issued the Scientific Literature Review (SLR) for this ingredient. According to the Dictionary, Benzyl Salicylate is reported to function mainly as a fragrance ingredient and light stabilizer. The Personal Care Products Council (Council) provided concentration of use survey data for the light stabilizer function (only) of Benzyl Salicylate. The results indicate that the light stabilizer concentrations of use for Benzyl Salicylate falls in the IFRA Standards for use of Benzyl Salicylate as a fragrance ingredient (identified as bensal122018data).
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Synthesis, Characterization and Biological Evaluation of New Potentially Active Hydrazones of Naproxen Hydrazide
    Available online a t www.derpharmachemica.com Scholars Research Library Der Pharma Chemica, 2015, 7(10):93-101 (http://derpharmachemica.com/archive.html) ISSN 0975-413X CODEN (USA): PCHHAX Synthesis, characterization and biological evaluation of new potentially active hydrazones of naproxen hydrazide Ali H. Abbas 1, Amer N. Elias 2*and Ammar A. Fadhil 3 1Department of Pharmaceutical Chemistry, College of Pharmacy, University of Tikrit, Salah-Aldin, Iraq 2Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad, Iraq 3Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad, Iraq _____________________________________________________________________________________________ ABSTRACT To synthesize new hydrazone derivatives of naproxen with enhanced anti-inflammatory activity and devoid the ulcerogenic side effects. Hydrazones were synthesized by conjugation of naproxen hydrazide with seven natural and synthetic aldehyde and ketone by using glacial acetic acid as catalyst. The synthesis has been carried out following simple methodology in excellent isolated yields.The structure of the synthesized derivatives has been characterized by elemental microanalysis (CHN), FTIR Spectroscopy, and other physicochemical properties.The anti- inflammatory activity of the synthesized compounds was evaluated in vivo using the egg-white induced edema model in rats, and the results of the biological assay was found to be comparable to Naproxen in this regard. The synthesizedhydrazone of
    [Show full text]
  • Safety Assessment of Benzyl Salicylate As Used in Cosmetics
    Safety Assessment of Benzyl Salicylate As Used in Cosmetics Status: Scientific Literature Review for Public Comment Release Date: October 9, 2018 Panel Meeting Date: December 3-4, 2018 All interested persons are provided 60 days from the above release date to comment on this safety assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Executive Director, Dr. Bart Heldreth. The 2018 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Alice Akinsulie, Scientific Writer/Analyst. © Cosmetic Ingredient Review 1620 L Street, NW, Suite 1200 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢ [email protected] INTRODUCTION This scientific literature review is the initial step in preparing a safety assessment of Benzyl Salicylate as used in cosmetic formulations.
    [Show full text]
  • Penetrating Pharmaceutical Foam Eindringender Pharmazeutischer Schaum Mousse Pharmaceutique Pénétrante
    (19) TZZ _T (11) EP 2 422 768 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/12 (2006.01) A61K 31/196 (2006.01) 15.04.2015 Bulletin 2015/16 A61K 31/167 (2006.01) A61Q 19/00 (2006.01) A61K 31/496 (2006.01) A61K 9/107 (2006.01) (2006.01) (2006.01) (21) Application number: 11190124.5 A61K 8/04 A61K 8/42 A61K 8/365 (2006.01) (22) Date of filing: 20.08.2004 (54) Penetrating pharmaceutical foam Eindringender pharmazeutischer Schaum Mousse pharmaceutique pénétrante (84) Designated Contracting States: • Raymond C Rowe, Paul J Sheskey and Marian E AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Quinn (Ed.): "Decyl oleate", Handbook of HU IE IT LI LU MC NL PL PT RO SE SI SK TR Pharmaceutical Excipients , 2011, pages 1-4, XP002666037, Retrieved from the Internet: URL: (30) Priority: 25.08.2003 US 497648 P http://www.medicinescomplete.com/mc/ex cipients/current/EXP-TD-c40-mn0001.htm?q=d (43) Date of publication of application: ecyloleate&t=search&ss=text&p=1#_hit 29.02.2012 Bulletin 2012/09 [retrieved on 2011-12-19] • Raymond C Rowe, Paul J Sheskey and Marian E (62) Document number(s) of the earlier application(s) in Quinn(Ed.): "Glyceryl Monooleate", Handbookof accordance with Art. 76 EPC: Pharmaceutical Excipients , 2011, pages 1-5, 04769356.9 / 1 663 148 XP002666038, Retrieved from the Internet: URL: http://www.medicinescomplete.com/mc/ex (73) Proprietor: Foamix Pharmaceuticals Ltd.
    [Show full text]
  • Chemical UVR Absorbers
    Chemical UVR Absorbers The names given in bold and used Diisopropyl methyl cinnamate Glyceryl ethyihexanoate dimethoxy- throughout this handbook are those of Empirical formula: cinnamate the International Nomenclature of C 6H22O2 Chemical names. Cosmetic Ingredients. Glyceryl octanoate dimethoxycinnamate; Chemical names: 2-propenoic acid, 3-(4-methoxyphenyl)-, 2-Propenoic acid, 3-12,4bis(1 diester with 1 ,3-dihydroxy-2-(2-ethyl-1 - methylethyphenyl-methyl ester; 2,5- oxohexyl)oxypropane diisopropyl methyl cinnamate _ lsoamyl-para-methoxycinnamate Ethyihexyl methoxycinnamate Empirical formula: Empirical formula: C151-12003 C 8H26O3 Chemical names: Cinnamates Chemical names: Amyl4-methoxycinnamate; isopentyl-4- 2-Ethylhexyl-4-methoxycin nam ate; methoxycinnamate; isopenlyl-para- Cinoxate 2-ethyl-hexyl-para-methoxycinnamate; methoxy-cinnamate; 3-(4-methoxyphenyl)- Empirical formula: para-methoxycinnamic acid, 2-ethylhexyl 2-propenoic acid, isopentyl ester Ci4HieO4 ester; 3-(4-methoxyphenyl)-2-propenoic acid, 2-ethylhexyl ester; octinoxate; octyl Trade names: Chemical names: methoxycinnamate; 2-propenoic acid, 3- Neo Heliopan type E 1000; Solarum AMC 2- Ethoxyothyl-para-methoxyci n nam ate; (4-methoxyphenyl)-2-ethylhexyl ester 2-propenoic acid, 3-(4-methoxyphery- para-A minobenzoic acids (PA BAs) 2-ethoxyethyl ester; 2-ethoxyethyl-4- Trade names: methoxycinnamate AEC Octyl Methoxycinnamate; Escalol Amyl dimethyl FABA 557; Eusolex 2292; Heliosol 3; Empirical formula: Trade names: Jeescreen OMC; Katoscreen OMC; Nec C14H21 NO2 Giv Tan F; Phiasol
    [Show full text]
  • Diclofenac Topical Solution Compared with Oral Diclofenac: a Pooled Safety Analysis
    Journal of Pain Research Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Diclofenac topical solution compared with oral diclofenac: a pooled safety analysis Sanford H Roth1 Background: Topical nonsteroidal anti-inflammatory drug (NSAID) formulations, which Philip Fuller2 produce less systemic exposure compared with oral formulations, are an option for the manage- ment of osteoarthritis (OA). However, the overall safety and efficacy of these agents compared 1Arizona Research and Education, Arthritis Laboratory, Arizona State with oral or systemic therapy remains controversial. University, Phoenix, AZ, USA; 2Medical Methods: Two 12-week, double-blind, double-dummy, randomized, controlled, multicenter Affairs, Covidien, Hazelwood, MO, USA studies compared the safety and efficacy profiles of diclofenac topical solution (TDiclo) with oral diclofenac (ODiclo). Each study independently showed that TDiclo had similar efficacy to ODiclo. To compare the safety profiles of TDiclo and ODiclo, a pooled safety analysis was performed for 927 total patients who had radiologically confirmed symptomatic OA of the knee. This pooled analysis included patients treated with TDiclo, containing 45.5% dimethyl sulfoxide (DMSO), and those treated with ODiclo. Safety assessments included monitoring of adverse events (AEs), recording of vital signs, dermatologic evaluation of the study knee, and clinical laboratory evaluation. Results: AEs occurred in 312 (67.1%) patients using TDiclo versus 298 (64.5%) of those tak- ing ODiclo. The most common AE with TDiclo was dry skin at the application site (24.1% vs 1.9% with ODiclo; P , 0.0001). Fewer gastrointestinal (25.4% vs 39.0%; P , 0.0001) and cardiovascular (1.5% vs 3.5%; P = 0.055) AEs occurred with TDiclo compared with ODiclo.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,086,858 Mceleney Et Al
    US006086858A United States Patent (19) 11 Patent Number: 6,086,858 McEleney et al. (45) Date of Patent: *Jul. 11, 2000 54). COLORED FORMULATIONS FOR 4,818,491 4/1989 Fariss. APPLICATION TO HUMAN SKIN 4.954,544 9/1990 Chandaria. 5,426.210 6/1995 Kato et al.. 75 Inventors: John McEleney, Newton; Wende SS 8.1. R el, Restry BMS Curtis A. Vock, 5,562,8962- - -2 10/1996 Repperepper et al..al. s 5,567,420 10/1996 McEleney et al. ....................... 424/60 5,609,852 3/1997 Galley et al.. 73 Assignee: IPA, LLC, Forth Worth, Tex. 5,753,210 5/1998 McEleney et al. ....................... 424/59 c: 5,955,062 9/1999 McEleney et al. ... ... 424/59 * Notice: This patent is Subject to a terminal dis- 5,958,383 9/1999 McEleney et al. ....................... 424/59 CC. OTHER PUBLICATIONS 21 Appl. No.: 09/333,088 Deposition Transcript of Jack Katz, Feb. 10, 1999, pp. 1-32, 22 Filled: 15, 1999 regarding civil action entitled, Playtex Products, Inc. and 22 File Jun. 15, Sun Pharmaceuticals Corporation vs. Schering-Plough Related U.S. Application Data Healthcare Products, Inc., Case No. 98–482-RPM, United States District Court, Middle District of Delaware. 63 Continuation of application No. 09/217,170, Dec. 21, 1998, First Amended Complaint, IPA v Schering-Plough et al., which is a continuation of application No. 09/024,458, Feb. Civil Action No. 98–482 (RRM), Jan. 22, 1999, 14 pages. ship, alengageplain E. Defendants' Answer & Counterclaims to First Amended ation of application N. Soss 64.
    [Show full text]
  • Dissolution of Cellulose in Dimethyl Sulfoxide. Effect of Thiamine Hydrochloride
    Polymer Journal, Vol. 22, No. 12, pp 1101-1103 (1990) SHORT COMMUNICATIONS Dissolution of Cellulose in Dimethyl Sulfoxide. Effect of Thiamine Hydrochloride Yoshihiro SHIGEMASA, Yutaka KISHIMOTO, Hitoshi SASHIWA, and Hiroyuki SAIMOTO Department of Materials Science, Faculty of Engineering, Tottori University, Koyama-cho, Tottori 680, Japan (Received August 2, 1990) KEY WORDS Cellulose / Dimethyl sulfoxide / Paraformaldehyde / Thiamin · HCl / Dissolution of cellulose has long been of paraformaldehyde (Merck Co.), and thia­ interest to investigators concerned with either min · HCl (Nakarai Tesque, Inc.) were used utilization of cellulose as a renewable resource without further purification. or effective methods to functionalize the In a typical experiment, avicel (1.0 g, polysaccharide. Although cellulose is insoluble 6.2 mmol per glucose residue), PF powder in neutral water and common organic solvent, (3.16 g, 0.1 mol as HCHO), and thiamin · HCl utilization in manufacture has shown that the (0.34 g, 1 mmol) were dispersed in DMSO polysaccharide is soluble in sulfuric acid, ( 100 ml) at room temperature. The mixture was aqueous solutions of zinc chloride, sodium then heated with rapid stirring at 90°C for 3 h. hydroxide, tetraalkylammonium hydroxide, Undissolved materials were removed by and cupric ammonium hydroxide. As an centrifugation (3,500 rpm, 5 min), followed by organic solvent, dimethyl sulfoxide containing washing with DMSO, methanol, and hot H 2O paraformaldehyde (DMSO/PF system) has to remove methylol groups. been found to be an excellent nondegrading The amounts of dissolved cellulose were solvent for cellulose. 1 - 3 In addition, studies estimated on the basis of the amounts of un­ have been reported on cellulose solvents dissolved cellulose.
    [Show full text]
  • Salicylate UV-Filters in Sunscreen Formulations Compromise the Preservative System Efficacy Against Pseudomonas Aeruginosa and Burkholderia Cepacia
    cosmetics Article Salicylate UV-Filters in Sunscreen Formulations Compromise the Preservative System Efficacy against Pseudomonas aeruginosa and Burkholderia cepacia Noa Ziklo, Inbal Tzafrir, Regina Shulkin and Paul Salama * Innovation department, Sharon Laboratories Ltd., Odem St. Industrial zone Ad-Halom, Ashdod 7898800, Israel; [email protected] (N.Z.); [email protected] (I.T.); [email protected] (R.S.) * Correspondence: [email protected]; Tel.: +972-54-2166476 Received: 15 July 2020; Accepted: 1 August 2020; Published: 3 August 2020 Abstract: Contamination of personal-care products are a serious health concern and therefore, preservative solutions are necessary for the costumers’ safety. High sun protection factor (SPF) sunscreen formulations are known to be difficult to preserve, due to their high ratio of organic phase containing the UV-filters. Salicylate esters such as octyl salicylate (OS) and homosalate (HS) are among the most common UV-filters currently used in the market, and can undergo hydrolysis by esterase molecules produced by contaminant microorganisms. The hydrolysis product, salicylic acid (SA) can be assimilated by certain bacteria that contain the chorismate pathway, in which its final product is pyochelin, an iron-chelating siderophore. Here, we show that OS and HS can compromise the preservative efficacy against two pathogenic important bacteria, Pseudomonas aeruginosa and Burkholderia cepacia. Challenge tests of formulations containing the UV-filters demonstrated that only bacteria with the chorismate pathway failed to be eradicated by the preservation system. mRNA expression levels of the bacterial pchD gene, which metabolizes SA to produce pyochelin, indicate a significant increase that was in correlation with increasing concentrations of both OS and HS.
    [Show full text]